Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

With people aged 65 years and older currently making up the fastest growing age group throughout the world, the demographic revolution of an aging society will inevitably lead to increased pressure to develop a rationalistic and age-tailored process of diagnosis and treatment among the elderly. As aging people often suffer from several chronic diseases and are being treated with multiple medications concurrently, unwanted drug interactions occur more frequently. Whereas recent approaches have recommended to remove particular drugs from the medication regimen to avoid adverse effects, Drug Therapy for the Elderly underlines both indispensable and dispensable elements of drug treatment, providing the practitioner with: - Background information on the elderly population regarding their needs for particular drugs (with an eye to frailty, co-morbidity patterns, and special sensitivities regarding drug metabolism and excretion) - Practical advice about drug treatment surveillance parameters in the elderly - In-depth discussion of drugs in relation to the elderly with specific diagnoses - Integration of multimorbidity/polypharmacy situations into prioritization schemes - A plan for how to deal with the complexity of polypharmacy situations in a five-minute consultation An original classification of drugs is proposed by the editor which relates the power of effects, prognostic data, and tolerability to a prioritization scoring system. This approach is the first to not only provide a negative listing, but also integrates positive data into an overall assessment for drugs fit for the aged. Therefore, Drug Therapy for the Elderly serves as a timely reference for a wide array of physicians.

Drug interactions. --- Geriatric pharmacology. --- Older people -- Drug use. --- Psychopharmacology. --- Chemotherapy --- Drugs --- Therapeutics --- Adult --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Age Groups --- Persons --- Named Groups --- Aged --- Drug Therapy --- Medicine --- Health & Biological Sciences --- Geriatrics --- Pharmacy, Therapeutics, & Pharmacology --- Older people --- Drug use --- Medicine. --- Pharmacology. --- Internal medicine. --- Geriatrics. --- Medicine & Public Health. --- Geriatrics/Gerontology. --- Internal Medicine. --- Pharmacology/Toxicology. --- Aging people --- Elderly people --- Old people --- Older adults --- Older persons --- Senior citizens --- Seniors (Older people) --- Age groups --- Gerontocracy --- Gerontology --- Old age --- Pharmacology --- Toxicology. --- Chemicals --- Poisoning --- Poisons --- Medicine, Internal --- Toxicology --- Diseases --- Health and hygiene --- Drug effects --- Medical pharmacology --- Medical sciences --- Pharmacy --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Principles of Translational Science in Medicine: From Bench to Bedside, Second Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing numbers of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine. Provides an in-depth description of novel tools for the assessment of translatability of trials to balance risk and improve projects at any given stage of product development New chapters deal with translational issues in the fastest growing population (the elderly), case studies, translatability assessment tools, and advances in nanotherapies Details IPR issues of translation, especially for public-private-partnerships Contains contributions from world leaders in translational medicine, including the former NIH director and authorities from various European regulatory institutions.

Medical innovations.